Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lupin Limited ( (IN:LUPIN) ) has provided an update.
Lupin Limited has announced updates regarding the transfer of its API R&D Division and Over-the-Counter Consumer Healthcare Business to its wholly owned subsidiaries. The Business Transfer Agreement for the API R&D Division with Lupin Manufacturing Solutions Limited is expected to be executed by June 30, 2025. Similarly, the transfer of the Over-the-Counter Consumer Healthcare Business to LUPINLIFE Consumer Healthcare Limited is also anticipated to be completed by the same date. These strategic moves aim to streamline operations and enhance the company’s focus on core business areas.
More about Lupin Limited
Lupin Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company has a significant presence in the global healthcare market, with a particular emphasis on providing affordable healthcare solutions.
YTD Price Performance: -10.88%
Average Trading Volume: 28,146
Current Market Cap: 962.3B INR
For an in-depth examination of LUPIN stock, go to TipRanks’ Stock Analysis page.